Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xarelto | Rivaroxaban | Venous thromboembolism, prevention | N/A | Complete | ||
Eliquis | Apixaban | Venous thromboembolic events, treatment and prevention of recurrence | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
Eliquis | Apixaban | Venous thromboembolic events, prevention | List with clinical criteria and/or conditions | Complete | ||
N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Active | ||
Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Bijuva | estradiol and progesterone | Vasomotor symptoms associated with menopause | Reimburse with clinical criteria and/or conditions | Complete | ||
Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete |